Back to search

Article

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Induced Neurocognitive Disorder: A Pharmacovigilance Study by Analyzing the Data from the U.S. FDA Adverse Event Reporting System

2021-12-08

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold>The neurocognitive disorder is a rare adverse event associated with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors in the randomized controlled trail (RCTs), there was limited evidence to prove their relation. This study aimed to assessing their association by detecting adverse signal in the FDA Adverse Event Reporting System (FAERS).<bold>Methods</...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
911f4426-e0c7-5a58-a66c-c17bef9d0ffb
DOI
10.21203/rs.3.rs-831924/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Induced Neurocognitive Disorder: A Pharmacovigilance Study by Analyzing the Data from the U.S. FDA Adverse Event Reporting SystemDOI 10.21203/rs.3.rs-831924/v1
Select a neighboring publication to make it the new centre.